MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy
Affected assets and topics
AnalystMarkets analysis
Why it matters
MediciNova has completed patient enrollment for its Phase 2 clinical trial evaluating MN-166 (ibudilast) in preventing chemotherapy-induced peripheral neuropathy, a common side effect of cancer treatment.
Expected market reaction
Market impact analysis based on bullish sentiment with 73% confidence.
Evidence trail
Evidence
AI provenance
Technical identifiers
- Provider tag
- groq-llama-3.1-8b-instant
- Analysis version
- groq-llama-3.1-8b-instant
- Article id
- 23965
Original source
LA JOLLA, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the successful completion of patient enrollment in the randomized, placebo-controlled Phase 2 clinical trial, the OXTOX study (Oxaliplatin Neurotoxicity study in patients with metastatic colorectal cancer). This study, an investigator-initiated clinical trial led
Read the full article on Yahoo Finance
Original article published by Yahoo Finance on December 18, 2025. Analysis and insights provided by AnalystMarkets AI.
This model on similar stories
Llama 3.1 8B Instant (Groq) · 33.3% correct across 45 scored calls on equities See the full record